The unique identifier for this trial on ClinicalTrials.gov is NCT01634685. 2a). If a woman has a genital herpes outbreak when she goes into labor, she may need a C-section (Cesarean delivery). . Our business could be affected by a number of other factors, including the risk factors listed from time to time in the company’s SEC reports including, but not limited to, the annual report on Form 10-K for the year ended April 30, 2010 and the quarterly report on Form 10-Q for the quarter ended October 31, 2010. Fusion of viral and cellular membranes is a basic entry mode for enveloped viruses, such as HIV and HCV , which still differ in specific aspects of viral entry and assembly, thus offering unique therapeutic opportunities. Our business could be affected by a number of other factors, including the risk factors listed from time to time in the company’s SEC reports including, but not limited to, the annual report on Form 10-K for the year ended April 30, 2010 and the quarterly report on Form 10-Q for the quarter ended October 31, 2010.
He believes that his Bavituximab study will redirect scientists’ attention on developing other drugs that exploit characteristics of infected host cells and believes this constitutes one of the most important aspects of his research. Peregrine Pharmaceuticals, Inc.recently reported publication of data in Nature Medicine that supports the broad anti-viral potential of the company’s novel anti-phosphatidylserine (anti-PS) antibody platform, showing that its PS-targeting drug bavituximab can cure lethal virus infections in animal disease models. Dr. Ipilimumab was tested in late-phase clinical trials by Jedd D. He added that one possibility is that guinea pigs are not inbred like mice (i.e., increased genetic variability) and that this is area for further study. Peregrine Pharmaceuticals, Inc. Bavituximab may address a fundamental “immune evasion” mechanism exploited by many infectious pathogens.
Our business could be affected by a number of other factors, including the risk factors listed from time to time in the company’s SEC reports including, but not limited to, the annual report on Form 10-K for the year ended April 30, 2011 and the quarterly report on Form 10-Q for the quarter ended January 31, 2012. 32. About Peregrine Pharmaceuticals Peregrine Pharmaceuticals, Inc. Dr. About Bavituximab’s Antiviral Approach Bavituximab is the first in a new class of patented antibody therapeutics that target and bind to phosphatidylserine (PS), a specific phospholipid component of cell membranes. Peregrine’s PS-targeting antibodies have been shown to help clear infectious virus from the bloodstream and to induce antibody-dependent cellular cytotoxicity. Mounting evidence shows PS to be an important part of the HIV infection process, particularly in regards to macrophage cells.
A growing body of scientific publications, including Nature Medicine and The Journal of Experimental Medicine, has highlighted data on the role of PS and Peregrine’s PS-targeting therapies in infectious diseases. By masking the exposed PS, bavituximab and other anti-PS antibodies may block these effects and allow the body to develop a robust immune response to the viral pathogen. disclaims any obligation, and does not undertake to update or revise any forward-looking statements in this press release. is a biopharmaceutical company with a portfolio of innovative monoclonal antibodies in clinical trials for the treatment of cancer and serious viral infections. The forward-looking statements involve risks and uncertainties including, but not limited to, the risk that results from ongoing trials will not be consistent with results experienced in earlier clinical trials and preclinical studies, the risk that Peregrine may experience delays in patient enrollment, risk that results may not support registration filings with the U.S. Factors that could cause actual results to differ materially or otherwise adversely impact the company’s ability to obtain regulatory approval for its product candidates include, but are not limited to, uncertainties associated with completing preclinical and clinical trials for our technologies; the early stage of product development; the significant costs to develop our products as all of our products are currently in development, preclinical studies or clinical trials; obtaining additional financing to support our operations and the development of our products; obtaining regulatory approval for our technologies; anticipated timing of regulatory filings and the potential success in gaining regulatory approval and complying with governmental regulations applicable to our business. Thorpe hopes that the FDA will adopt this attitude.
Coinfected patients typically have higher HCV viral loads and more rapid progression compared to patients infected with HCV alone. Solid Cancers (India n=12, 11/2006-5/2007) 3. But the truth is that most of those nagging, annoying sores that you call either cold sores or fever blisters really are herpes cold sores. Any thoughts? (NASDAQ: PPHM), a clinical-stage biopharmaceutical company developing first-in-class monoclonal antibodies for the treatment of cancer and viral infections, today announced preclinical data demonstrating its lead antibody bavituximab’s ability to bind to virus particles and virus-infected cells of five viruses that cause viral hemorrhagic fever (VHF), including the highly lethal Ebola virus.